NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq:NAMS) will present multiple obicetrapib and lipid management data sets at the National Lipid Association (NLA) 2026 Scientific Sessions, held June 11–14, 2026 in Chicago.

Posters on obicetrapib safety, kidney and liver function, pharmacokinetics, HDL remodeling, and real-world statin use are scheduled for June 12.

News Market Reaction – NAMS

+1.26%

+1.26% Session close to close

In the Jun 3 session, NAMS gained 1.26%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights a broad slate of NLA 2026 presentations covering obicetrapib’s safety, ...

Analysis

This announcement highlights a broad slate of NLA 2026 presentations covering obicetrapib’s safety, pharmacokinetics, kidney function, and real-world statin use. It reinforces the clinical narrative built in prior updates, including the Q1 2026 report noting $707.3M in cash and active Phase 3 programs. Investors may focus on how these analyses complement existing BROADWAY/BROOKLYN data and support the overall risk–benefit profile ahead of larger cardiovascular outcome readouts and future regulatory decisions.

Key Figures

Conference dates: June 11–14, 2026 Presentation date: June 12, 2026 Abstract number: 353 +5 more

8 metrics

Conference dates June 11–14, 2026 NLA 2026 Scientific Sessions in Chicago

Presentation date June 12, 2026 Multiple obicetrapib-related presentations at NLA 2026

Abstract number 353 Novel cholesterol lowering drugs presentation

Abstract number 220 Mediation analysis on LDL-C and Lp(a) from BROADWAY/BROOKLYN MACE data

Abstract number 165 Integrated Phase III safety analysis of obicetrapib

Abstract number 182 Kidney function results from BROADWAY trial

Abstract number 249 Pharmacokinetics and safety in moderate hepatic impairment

Abstract number 251 CETP inhibition and HDL2/ApoM/S1P/ApoA1/xanthophyll changes

Historical Context

5 past events · Latest: May 28 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 28	Investor conferences	Neutral	-3.1%	Participation in two June 2026 healthcare investor conferences with webcasts.
May 11	Investor conferences	Neutral	+2.2%	Announcement of two May 2026 healthcare and biopharma investor conferences.
May 07	Earnings update	Positive	+12.5%	Q1 2026 results with $707.3M cash and ongoing Phase 3 programs detailed.
May 01	Equity grants	Neutral	+5.0%	Inducement options and RSUs granted to new hires under 2024 Inducement Plan.
Apr 08	Conference appearance	Neutral	+0.3%	Needham virtual healthcare conference fireside chat with webcast access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news flow (conferences, earnings, grants) has generally seen price moves align directionally with the perceived tone of the announcements, with the strongest move following the Q1 2026 update.

Recent Company History

Over the past few months, NewAmsterdam has focused on investor visibility and clinical progress. In April–May 2026, it announced multiple healthcare conference appearances and participation at investor events, typically prompting modest price reactions. The May 7, 2026 Q1 update highlighted cash of $707.3M and ongoing Phase 3 programs, coinciding with a +12.46% move. Inducement equity grants on May 1, 2026 and other routine updates drove smaller, generally aligned moves. Today’s NLA presentation lineup fits this pattern of visibility-focused news.

Key Terms

low-density lipoprotein cholesterol, ldl-c, cardiovascular disease, hypercholesterolemia, +2 more

6 terms

low-density lipoprotein cholesterol medical

"patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”)"

A form of cholesterol carried in the blood that tends to deposit fatty material on artery walls, often called “bad” cholesterol; think of LDL as delivery trucks that sometimes drop sticky cargo along the body’s highways. Investors monitor LDL because drugs, medical devices, and diagnostic tests that change LDL levels or how they’re managed can drive healthcare spending, regulatory approvals, and company earnings, affecting valuations and risk in health-related businesses.

ldl-c medical

"elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies"

LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.

cardiovascular disease medical

"non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated"

A group of conditions that affect the heart and blood vessels, such as heart attacks, strokes and clogged arteries. Think of the cardiovascular system as a body’s plumbing and engine: when pipes narrow or the pump fails, treatment, devices and long-term care become necessary. Investors watch these diseases because their prevalence drives demand for drugs, devices and services, influences healthcare costs and insurer payouts, and affects workforce productivity and regulatory risk.

hypercholesterolemia medical

"therapy for hypercholesterolemia, at the National Lipid Association (NLA) 2026"

Hypercholesterolemia is a medical condition where blood contains persistently high levels of cholesterol, a fatty substance that can build up in arteries and raise the risk of heart disease. For investors it matters because it drives demand for treatments, influences healthcare costs and insurance spending, and shapes the commercial outlook for drug makers, medical devices, and public health programs—like a steady customer base for therapies aimed at lowering cholesterol.

pharmacokinetics medical

"Title: Pharmacokinetics and Safety of Obicetrapib in Moderate Hepatic Impairment"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

cetp inhibition medical

"Title: CETP Inhibition With Obicetrapib Preserved Kidney Function in Patients"

CETP inhibition is a drug mechanism that blocks a protein (cholesteryl ester transfer protein) that normally moves cholesterol between different blood carriers, so that protective “good” cholesterol levels rise while levels of harmful particles may fall or change. For investors, CETP inhibitors matter because they represent a pathway to treat heart disease risk; success or failure in clinical trials, safety signals, or regulatory decisions can strongly affect a drug developer’s value, much like a traffic controller changing the flow of vehicles alters congestion patterns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the National Lipid Association (NLA) 2026 Scientific Sessions, taking place on June 11 – 14, 2026 in Chicago, Illinois.

Presentation details are as follows:

Title: Novel Cholesterol Lowering Drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?
Abstract Number: 353
Date and Time: Friday, June 12, 2026 at 3:50 PM CDT
Location: Kiosk #35
Presenter: Charles Shear

Title: Mediation Analysis on LDL-C and LPa from Pooled Broadway and Brooklyn MACE Data
Abstract Number: 220
Date and Time: Friday, June 12, 2026 at 10:30 AM CDT
Location: Kiosk #35
Presenter: Michael Szarek, Ph.D.

Title: Safety of Obicetrapib: An Integrated Phase III Safety Analysis
Abstract Number: 165
Date and Time: Friday, June 12, 2026 at 10:30 AM CDT
Location: Kiosk #4
Presenter: Adam J. Nelson, Ph.D.

Title: CETP Inhibition With Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results From the BROADWAY Trial
Abstract Number: 182
Date and Time: Friday, June 12, 2026 at 1:50 PM CDT
Location: Kiosk #40
Presenter: Liffert Vogt, M.D., Ph.D.

Title: Pharmacokinetics and Safety of Obicetrapib in Moderate Hepatic Impairment: Phase I Study Results
Abstract Number: 249
Date and Time: Friday, June 12, 2026 at 3:50 PM CDT
Location: Kiosk #4
Presenter: John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, NewAmsterdam Pharma

Title: Obicetrapib CETP inhibition remodels HDL2 and raises ApoM, S1P, ApoA1 monomers, boosting plasma xanthophyll and carotenoid levels
Abstract Number: 251
Date and Time: Friday, June 12, 2026 at 1:50 PM CDT
Location: Kiosk #55
Presenter: Eric J. Niesor, Ph.D.

Title: Cardiovascular Events in People with Normal Low-Density Lipoprotein Cholesterol Levels but Discordantly High Levels of Small/Medium LDL Particles
Abstract Number: 262
Date and Time: Friday, June 12, 2026 at 3:50 PM CDT
Location: Kiosk #43
Presenter: Floriaan Schmidt, Ph.D.

Title: Intolerance and Adverse Events with High-Intensity Statin Therapy in Real-World Practice
Abstract Number: 322
Date and Time: Friday, June 12, 2026 at 1:50 PM CDT
Location: Kiosk #7
Presenter: Jennifer A. Kammerer, Pharm.D., MMI, CPHIMS, Director, HEOR Research, NewAmsterdam Pharma

Title: Suboptimal Adherence and LDL-C Goal Attainment with High Intensity versus Moderate to-Low Intensity Statins in Real-World Practice
Abstract Number: 323
Date and Time: Friday, June 12, 2026 at 3:50 PM CDT
Location: Kiosk #7
Presenter: Jennifer A. Kammerer, Pharm.D., MMI, CPHIMS, Director, HEOR Research, NewAmsterdam Pharma

About Obicetrapib
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

FAQ

What is NewAmsterdam Pharma (NAMS) presenting at the NLA 2026 Scientific Sessions?

NewAmsterdam Pharma is presenting multiple posters focused on obicetrapib and lipid management at NLA 2026. According to NewAmsterdam, topics include phase 2/3 safety assessments, MACE data mediation analyses, kidney and liver function, HDL remodeling, and real-world statin intolerance and adherence.

When will NewAmsterdam Pharma (NAMS) present obicetrapib data at NLA 2026?

NewAmsterdam will present obicetrapib-related data on Friday, June 12, 2026, at NLA 2026. According to NewAmsterdam, presentations occur throughout the day at different kiosks, covering safety analyses, BROADWAY trial kidney function results, hepatic impairment pharmacokinetics, and HDL remodeling effects.

Which obicetrapib safety and efficacy topics will NewAmsterdam (NAMS) highlight at NLA 2026?

NewAmsterdam will highlight several obicetrapib safety and outcomes-related topics at NLA 2026. According to NewAmsterdam, these include integrated phase 3 safety, phase 2/3 safety assessments versus cardiovascular outcomes, BROADWAY trial kidney function findings, and pharmacokinetics and safety in patients with moderate hepatic impairment.

Who are the key NewAmsterdam Pharma presenters for obicetrapib at NLA 2026?

Key presenters include John Kastelein, Michael Szarek, Adam J. Nelson, Liffert Vogt, and Eric J. Niesor. According to NewAmsterdam, these experts will cover pharmacokinetics, integrated phase 3 safety, BROADWAY kidney outcomes, HDL remodeling, and mediation analyses of LDL-C and Lp(a) from Broadway and Brooklyn MACE data.

What real-world statin use research will NewAmsterdam (NAMS) share at NLA 2026?

NewAmsterdam will share data on statin intolerance, adverse events, and LDL-C goal attainment in practice. According to NewAmsterdam, Jennifer A. Kammerer will present two posters on high-intensity statin intolerance and on adherence and LDL-C goal achievement with high- versus moderate-to-low intensity statins.

Where will NewAmsterdam Pharma posters be located at NLA 2026 in Chicago?

NewAmsterdam posters will be presented at various kiosks within the NLA 2026 venue. According to NewAmsterdam, kiosk locations include #4, #7, #35, #40, #43, and #55, all scheduled for Friday, June 12, 2026, at specific times.